Takeda, University Reverse Process, With Firm To Receive Royalties
This article was originally published in PharmAsia News
Executive Summary
Reversing the usual drug route to development, Takeda Pharmaceutical has provided the University of Tokyo its drug for clinical trials for treating Alzheimer's disease, with the Japan-based drug maker to receive royalties.